Viread/Clevudine Combination Goes Head-To-Head Against Monotherapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead and Pharmasset study two-drug combo versus each alone for treatment of hepatitis B.
You may also be interested in...
As It Prepares for a Future with Wyeth, Pfizer Reports Ho-Hum Q1 Results
Pfizer’s first-quarter results were down, but in line with the company’s and Wall Street’s expectations.
Gilead’s Viread In HBV Shores Up Flagging Sales For Drug In HIV
Analyst suggests $300 million additional revenue from Viread’s HBV indication.
Gilead’s Viread In HBV Shores Up Flagging Sales For Drug In HIV
Analyst suggests $300 million additional revenue from Viread’s HBV indication.